文献速递鼻科

遗传性出血性毛细血管扩张症鼻出血的局部鼻内治疗:系统综述

Topical Intranasal Treatments for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.
PubMed 文献 · Otolaryngol Head Neck Surg · 2026-08-26

该系统综述检索MEDLINE、Embase、CENTRAL、ClinicalTrials.gov和WHO-ICTRP至2025年5月,纳入20项研究共590例成人HHT鼻出血患者,评估局部鼻内治疗的有效性。结果显示组内ESS下降常见,但随机对照试验中无局部治疗类别持续优于安慰剂,贝伐珠单抗在病例系列中ESS降幅最大(均值-3.3,n=26),不良事件少见且多为轻度局部刺激。结论认为现有证据不支持局部单药治疗具有超越安慰剂的持久或临床意义疗效,但局部药物仍可作为耳鼻咽喉科医生在系统治疗前的辅助选择。

要点

  • 随机对照试验中无局部治疗类别持续优于安慰剂。
  • 贝伐珠单抗在病例系列中ESS降幅最大(均值-3.3,n=26)。
  • 局部药物仍可作为HHT鼻出血的辅助治疗选项。

核心结论

  • 现有证据不支持局部鼻内单药治疗对HHT相关鼻出血具有超越安慰剂的持久或临床意义疗效。
  • 疗效证据的缺失反映结构性证据缺口,而非缺乏生物学合理性或患者获益。
  • 局部药物仍可作为耳鼻咽喉科医生在系统治疗前的辅助选择。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase、CENTRAL、ClinicalTrials.gov和WHO-ICTRP至2025年5月。
  • 纳入20项英文研究,共590例接受局部药物治疗鼻出血的成人HHT患者。
  • 采用Covidence按PRISMA指南进行筛选和数据提取,使用JBI清单评估偏倚风险,因异质性采用叙述性综合。

主要发现

  • 组内ESS下降常见,但随机对照试验中无局部治疗类别持续优于安慰剂。
  • 贝伐珠单抗在病例系列中ESS降幅最大(均值-3.3,n=26)。
  • 所有药物不良事件少见,主要限于轻度局部刺激。

临床怎么用

  • 局部鼻内药物可作为HHT相关鼻出血的前线辅助治疗,在系统治疗前使用。
  • 选择药物时应考虑HHT表型异质性和治疗反应的生物学变异性。
  • 本综述为多模式HHT治疗中的循证药物选择提供框架。

局限性

  • 研究间异质性大,结果仅作叙述性综合。
  • 随机对照试验中无局部治疗类别持续优于安慰剂,证据存在结构性缺口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the landscape of topical intranasal therapies in hereditary hemorrhagic telangiectasia (HHT) associated epistaxis, evaluate comparative effectiveness versus placebo, and define their potential adjunctive role within evolving treatment paradigms. DATA SOURCES: MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, and the WHO-ICTRP were searched through May 2025. REVIEW METHODS: English-language studies of adults with HHT treated with topical agents for epistaxis were included. Study selection and data extraction were performed using Covidence in accordance with PRISMA guidelines. Risk of bias was assessed using Joanna Briggs Institute (JBI) checklists. Due to study heterogeneity, results were synthesized narratively. RESULTS: Of 310 records, 20 studies met inclusion (n = 590). Within-group reductions in Epistaxis Severity Score (ESS) were frequently observed; however, no topical class demonstrated consistent superiority over placebo in randomized controlled trials. Bevacizumab showed the largest reduction in ESS among case series (mean -3.3, n = 26). Across all agents, adverse events were uncommon and primarily limited to mild localized irritation. CONCLUSIONS: Current evidence does not support durable or clinically meaningful efficacy of topical intranasal monotherapy beyond placebo for HHT-related epistaxis. However, this absence of definitive efficacy reflects a structural evidence gap rather than a lack of biologic plausibility or patient-centered benefit. Given the phenotypic heterogeneity of HHT and the biologic variability in treatment response, topical agents remain clinically relevant as frontline adjunctive options for otolaryngologists managing this condition before systemic therapies become necessary. This review provides a framework for evidence-informed agent selection in the context of multimodal HHT care.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Scharfenberger T, Kwon M, Elased R, et al. Topical Intranasal Treatments for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review. Otolaryngol Head Neck Surg. 2026. PMID: 42647059. doi:10.1002/ohn.70412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。